Corporate Update: Zhejiang Jiuzhou Pharmaceutical
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (603456.SS) remained unchanged at the 06:55 AM Central Europe close on Friday, 23 March. The share price held steady, reflecting a neutral market sentiment over the 24‑hour trading window. Presently, one share can be acquired for approximately CNH 16.10 on the Shanghai Stock Exchange.
Market Snapshot
- Outstanding Shares: 881.7 million
- Market Capitalisation: CNH 2.00 billion
- Volume (last 24 h): CNH 284.30 million
- Year‑to‑Date Performance: Down 3.36 % since the end of February
- 200‑Day Simple Moving Average: CNH 14.95
- 52‑Week High: CNH 22.25 (17 November 2025)
- 52‑Week Low: CNH 12.05 (11 June 2026)
Comparative Peer Activity
| Company | Ticker | 24‑h Movement | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Slie | 300543.SZ | 0 % | CNY 6.93 | CNY 2.30 billion |
| Guolin | 300786.SZ | 0 % | CNY 11.62 | CNY 2.30 billion |
| Xtkj | 300615.SZ | 0 % | CNY 10.33 | CNY 2.30 billion |
| Henan Huanghe Whirlwind | 600172.SS | 0 % | CNH 10.86 | CNH 2.40 billion |
| Laekna | 2105.HK | –7.9 % | HKD 5.50 | HKD 2.60 billion |
The near‑static movement across most peers underscores a period of consolidation within the pharmaceutical sector, with Laekna displaying the most significant decline among the listed names.
Company Overview
Zhejiang Jiuzhou Pharmaceutical, headquartered in Taizhou, China, operates within the health‑care industry, focusing on the development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Its product portfolio spans several therapeutic classes, including central nervous system agents, non‑steroidal anti‑inflammatory drugs, anti‑infective agents, and hypoglycemic medications. For further details on product offerings and corporate initiatives, the company maintains an information portal at www.jiuzhoupharma.com .
This article synthesises publicly available trading data and corporate disclosures to provide a concise overview of Zhejiang Jiuzhou Pharmaceutical’s recent market activity and operational context.
